FDA Approves Inluriyo for Advanced Breast Cancer

Breast Cancer -On September 25, 2025, the U.S. Food and Drug Administration granted approval to imlunestrant (brand name: Inluriyo, from Eli Lilly and Company) for the treatment of adults with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, whose disease progressed after at least one line of endocrine (hormone) therapy.

Background & Indication

On September 25, 2025, the U.S. Food and Drug Administration granted approval to imlunestrant (brand name: Inluriyo, from Eli Lilly and Company) for the treatment of adults with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, whose disease progressed after at least one line of endocrine (hormone) therapy.

In parallel, the FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify ESR1 mutations in eligible patients.

This approval introduces a new oral therapeutic option specifically for patients whose tumor has evolved under prior hormone therapy, with molecular resistance changes (i.e. ESR1 mutations).

Mechanism of Action & Rationale

ESR1 mutations (mutations in the estrogen receptor gene) are known to emerge under selective pressure from endocrine therapy. These mutations can make the estrogen receptor aberrantly active, contributing to resistance.
Imlunestrant / Inluriyo is an oral estrogen receptor antagonist / degrader (often classed as a selective estrogen receptor degrader, or SERD). It binds the estrogen receptor, blocks its activity, and promotes its degradation — ideally overcoming resistance mediated by ESR1 mutation.
Its oral formulation is a differentiator relative to older agents like fulvestrant, which must be given via injection.

Evidence & Clinical Trial (EMBER-3)

The pivotal data for the approval come from the phase III EMBER-3 trial (clinicaltrials.gov identifier NCT04975308).

Design & Population

Patients enrolled had ER-positive, HER2-negative, advanced or metastatic breast cancer, previously treated with an aromatase inhibitor (with or without CDK4/6 inhibition).
ESR1 mutational status was assessed by circulating tumor DNA (ctDNA) using the Guardant360 CDx assay. Only selected ESR1 ligand-binding domain mutations were included.
Within the ESR1-mutated subgroup (n = 256), patients were randomized to imlunestrant vs investigator’s choice of endocrine therapy (fulvestrant or exemestane).

Efficacy Results

Progression-Free Survival (PFS) (investigator assessed) was 5.5 months in the imlunestrant arm vs 3.8 months in the endocrine therapy arm (hazard ratio 0.62; 95% CI 0.46–0.82; p = 0.0008).
This corresponds to a 38% reduction in the risk of disease progression or death.
The objective response rate (ORR) in patients with measurable disease was 14.3% in the imlunestrant arm vs 7.7% in the control arm.
Overall survival (OS) data remain immature at time of approval, with ~31% of deaths observed in the ESR1-mutated population.

Safety & Dosing

The recommended dosage is 400 mg orally once daily (as two 200 mg tablets) on an empty stomach (≥2 hours before or ≥1 hour after food), continued until disease progression or unacceptable toxicity.
Adverse events observed in ≥10% of patients, including laboratory abnormalities, were:
• Decreased hemoglobin
• Musculoskeletal pain
• Decreased calcium
• Neutropenia
• Elevated AST/ALT (liver enzymes)
• Fatigue
• Diarrhea
• Increased triglycerides
• Nausea, constipation
• Elevated cholesterol
• Abdominal pain
About 4.6% of patients discontinued treatment because of adverse events, 2.4% required dose reductions, and 10% had treatment interruptions.
A key warning is embryo-fetal toxicity — the drug may harm a developing fetus.

Significance & Future Directions

The approval of Inluriyo marks a significant advance in the treatment landscape by offering a targeted oral therapy for patients with ESR1-mutated metastatic breast cancer — a population with endocrine therapy resistance.
Its oral formulation gives convenience and potentially better accessibility compared to injectable alternatives.
Inluriyo joins a growing class of novel oral SERDs; for example, Orserdu is another oral SERD already approved in 2023.
Ongoing studies include the EMBER-4 trial, evaluating imlunestrant in the adjuvant setting (early-stage disease) to prevent recurrence.
Also, combinations of imlunestrant with other agents (e.g. CDK4/6 inhibitors like abemaciclib) are under investigation to potentially improve outcomes further.
The companion diagnostic (Guardant360 CDx) approval underscores the continuing role of precision medicine, using circulating tumor DNA assays to guide tailored therapy.